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Objectives The goal of this research was to assess non-inferiority of the next-generation TAXUS Liberté stent (Boston Scien-
tific Corp., Natick, Massachusetts) versus the TAXUS Express stent (Boston Scientific Corp.).
Background The introduction of drug-eluting stents (DES) has shifted clinical practice towards more complex lesion subsets,
prompting the need for more deliverable DES. TAXUS Liberté was designed to combine the established polymer-
based, paclitaxel-elution TAXUS technology with the more advanced Liberté stent platform.
Methods The TAXUS ATLAS study is a global, prospective, single-arm trial evaluating outcomes in de novo coronary le-
sions visually estimated to be 10 to 28 mm in length in vessels 2.5 to 4.0 mm in diameter. The control group is
an entry-criteria-matched population of TAXUS Express patients from the TAXUS IV and V trials. The primary end
point is non-inferiority of TAXUS Liberté versus TAXUS Express for 9-month target vessel revascularization.
Results Despite similar inclusion criteria, quantitative coronary angiography-determined baseline lesion characteristics
were significantly more complex for TAXUS Liberté than TAXUS Express. The primary non-inferiority end point
was met with the 1-sided 95% confidence bound of 2.98% less than the pre-specified non-inferiority margin of
3% (p  0.0487).
Conclusions Despite the treatment of more complex lesions with TAXUS Liberté, the primary end point was met, demonstrat-
ing that TAXUS Liberté is non-inferior to TAXUS Express. The successful transfer of the proven TAXUS technology
to the more advanced TAXUS Liberté platform was demonstrated. (TAXUS ATLAS: TAXUS Liberté-SR Stent for the
Treatment of De Novo Coronary Artery Lesions; http://www.clinicaltrials.gov/ct/show/NCT00371709?order1;
NCT00371709) (J Am Coll Cardiol 2007;49:1676–83) © 2007 by the American College of Cardiology
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April 24, 2007:1676–83 The TAXUS ATLAS Trialhe effectiveness of first-generation drug-eluting stents (DES)
n reducing restenosis after percutaneous coronary intervention
as been established (1–3). While reducing restenosis in all
esion and patient populations studied, the use of first-
eneration DES in more complex lesions has been limited by
tent design.
The next-generation TAXUS Liberté (Boston Scientific
orp., Natick, Massachusetts) paclitaxel-eluting stent plat-
orm was developed to improve deliverability, conformabil-
ty, and drug distribution homogeneity while maintaining
he established antirestenotic properties of the TAXUS
olymer-based, paclitaxel-elution technology. Since both
tents use the same drug-eluting technology, we hypothe-
ized that TAXUS Liberté would be as safe and effective as
AXUS Express (Boston Scientific Corporation) while
eing more deliverable. Therefore, we initiated the prospec-
ive, single-arm, non-inferiority TAXUS ATLAS trial to
valuate the safety and efficacy of TAXUS Liberté versus
istorical TAXUS Express controls in single, de novo coronary
esions.
ethods
evice description. Both TAXUS Express2-SR and
AXUS Liberté-SR consist of a balloon-expandable stent
ith a polymer coating containing 1 g/mm2 of paclitaxel
n a slow-release formulation on the Express or Liberté
latforms, respectively (Fig. 1).
Figure 1 Study Devices
(A) TAXUS Express. (B) TAXUS Liberté.(atient selection and study
ow. A total of 871 patients
ere enrolled at 61 centers in 7
ountries in North America and
sia Pacific from August 2004 to
ebruary 2005 to receive the
AXUS Liberté stent. Eligible
atients were 18 years old with
single de novo lesion 10 and
28 mm in length (by visual
stimate) in a native coronary
rtery with a reference vessel di-
meter of 2.5 and 4.0 mm
by visual estimate). Patients
ith acute (72 h) myocardial
nfarction (MI), left main dis-
ase, ostial or bifurcation lesions, total occlusion or throm-
us, calcification, or tortuosity were excluded. Additional
tudy stents were allowed in the target lesion when clinically
ndicated for bailout reasons. The study protocol was
pproved by local ethics review committees. All patients
rovided written informed consent.
Loading doses of clopidogrel (300 mg) or ticlopidine
500 mg) and aspirin (300 mg) were administered before
tent implantation. After implantation, all patients were
rescribed clopidogrel (75 mg daily) or ticlopidine (250
g twice daily) for a minimum of 6 months, and aspirin
100 mg daily) for at least 9 months but recommended
ndefinitely.
Clinical follow-up was scheduled at 1, 4, and 9 months
nd yearly thereafter for 5 years. Follow-up quantitative
oronary angiography (QCA) and intravascular ultrasound
ere scheduled at 9 months for a randomized subset of
atients (Fig. 2A).
ontrol group. The control group consisted of a historical
opulation of TAXUS Express-SR patients from the
AXUS IV and V trials (2,3); inclusion and exclusion
riteria were similar to those for the TAXUS ATLAS trial
Fig. 2B).
ata management and definitions. Independent moni-
ors verified all data from case report forms. Stent throm-
osis, death, and major adverse cardiac events (MACE),
ncluding cardiac death, MI, and target vessel revasculariza-
ion (TVR), were adjudicated by an independent Clinical
vents Committee. A data monitoring committee periodi-
ally reviewed safety data. The clinical and angiographic end
oint definitions were identical to those in the TAXUS IV
nd V trials (2,3).
Blinded angiographic analysis was performed using vali-
ated quantitative methods (4). The same core lab (Brigham
nd Women’s Hospital, Boston, Massachusetts) and proce-
ures were used as for the TAXUS IV and V trials.
re-specified non-inferiority end points. The primary
nd point was 9-month TVR. In-stent percent diameter
tenosis, binary restenosis, minimum lumen diameter
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
ITT  intention-to-treat
MACE  major adverse
cardiac events
MI  myocardial infarction
MLD  minimum lumen
diameter
PP  per protocol
QCA  quantitative
coronary angiography
TVR  target vessel
revascularizationMLD), and late loss were also tested for non-inferiority.
S
i
p
e

a
c
i
p
(
t
p
i
t
1678 Turco et al. JACC Vol. 49, No. 16, 2007
The TAXUS ATLAS Trial April 24, 2007:1676–83tatistical methodology. P values are 2-sided unless spec-
fied otherwise. Student t test was used to compare inde-
endent continuous variables, while chi-square or Fisher
xact test was used to compare proportions. A p value of
0.05 was considered statistically significant. Kaplan-Meier
nalysis was used to assess time-to-event outcomes. Baseline
haracteristics and 9-month end points are reported for the
Figure 2 Study Flow and Control Group Selection
(A) The TAXUS ATLAS study flow. (B) Selection of the TAXUS Express control grou
TAXUS ATLAS trial. All 662 TAXUS Express patients from the TAXUS IV trial were in
for reference vessel diameter (RVD) 2.5 mm, lesion length 28 mm, or 1 stud
F/U  follow-up; ITT  intention-to-treat population; IVUS  intravascular ultrasountention-to-treat (ITT) population, while 12-month end coints are reported for the per-protocol (PP) population
excludes patients without study stent). Non-inferiority
esting for the primary end point was performed on both
opulations, but the main population of interest was PP.
For the primary end point, the pre-specified, non-
nferiority margin of 3.0% was based on one-third of the
reatment effect with TAXUS Express versus the bare metal
ents from the TAXUS IV and V trials were selected based on entry criteria for the
. Of the 577 TAXUS Express patients in the TAXUS V trial, 248 were excluded
t planned for implantation. *Based on visual estimate. Angio  angiography;
 per-protocol population.p. Pati
cluded
y sten
nd; PPontrol observed in the TAXUS IV trial (2). Margins for
n
a
t
9
1
A
ease; P
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April 24, 2007:1676–83 The TAXUS ATLAS Trialon-inferiority testing of secondary QCA end points were
lso pre-specified based on results from the TAXUS IV
rial. Assuming a non-inferiority margin of 3.0%, a
Baseline Patient Characteristics
Table 1 Baseline Patient Characteristics
TA
Men 72.6
Age (yrs) 62.7
Cardiac history
Stable angina 52.8
Unstable angina 34.4
Silent ischemia 12.8
Previous PCI 31.4
Previous CABG 10.3
Cardiac risk factors
Smoking, ever 64.0
Diabetes, medically treated 24.6
Insulin-dependent 7.7
Hyperlipidemia 67.1
Family history of CAD 55.2
Lesion characteristics (by visual estimation)
Lesion length, mm 15.5
RVD, mm 3.14
Numbers are % (count/sample size) or mean  SD (n). Data for the i
CABG  coronary artery bypass graft; CAD  coronary artery dis
diameter.
Baseline Lesion Characteristics Determined by
Table 2 Baseline Lesion Characteristics Det
TAXUS Expr
(n  991
Target lesion vessel
LAD 40.6% (400/9
Circumflex 27.6% (272/9
RCA 31.7% (312/9
LMCA 0.1% (1/985
Lesion location
Ostial 3.7% (36/98
Proximal 37.9% (372/9
Mid 50.0% (491/9
Distal 8.5% (83/98
RVD (mm) 2.79  0.49 (
%DS 66.8  10.8 (
MLD (mm) 0.92  0.34 (
Lesion length (mm) 13.60  6.11 (
Eccentric lesion 46.9% (461/9
Bend (degrees) 25.91  18.45
Tortuosity 8.4% (82/98
Calcification 23.1% (227/9
Aneurysm 1.7% (17/98
Branch vessel disease 5.0% (49/98
Modified ACC/AHA lesion type
A 8.6% (85/98
B1 30.1% (296/9
B2 or C 61.2% (602/9
Numbers are % (count/sample size) or mean  SD (n). Data for the i
ACC  American College of Cardiology; AHA  American Heart Assartery; MLDminimum lumen diameter; QCA quantitative coronary angiog
%DS  % diameter stenosis.-month TVR rate of 5.7% (from the TAXUS IV trial), and
0% attrition, the required enrollment for the TAXUS
TLAS trial was 822 subjects for 80% power.
xpress
91)
TAXUS Liberté
(n  871) p Value
9/991) 69.5% (605/871) 0.1514
.2 (991) 61.9  10.7 (871) 0.1461
3/991) 60.2% (524/871) 0.0015
1/991) 32.1% (280/871) 0.3246
7/991) 7.6% (66/871) 0.0002
1/991) 30.8% (268/871) 0.8020
2/991) 5.5% (48/871) 0.0002
4/991) 65.9% (574/871) 0.4082
4/991) 25.3% (220/871) 0.7884
/991) 7.8% (68/871) 0.9309
5/991) 76.3% (665/871) 0.0001
7/991) 50.5% (440/871) 0.0455
(990) 15.8  5.5 (871) 0.1298
3 (990) 3.09  0.48 (871) 0.0177
-to-treat population are shown.
CI  percutaneous coronary intervention; RVD  reference vessel
ned by QCA
TAXUS Liberté
(n  871) p Value
0.6693
41.7% (362/869) 0.6704
25.7% (223/869) 0.3444
32.7% (284/869) 0.6541
0.0% (0/869) 1.0000
0.3558
2.4% (21/869) 0.1384
40.3% (350/869) 0.2940
49.5% (430/869) 0.8522
7.8% (68/869) 0.6708
2.75  0.50 (869) 0.1274
69.1  11.8 (869) 0.0001
0.85  0.36 (869) 0.0001
14.76  6.61 (869) 0.0001
51.4% (447/869) 0.0562
33.77  17.83 (869) 0.0001
13.1% (114/869) 0.0011
29.8% (259/869) 0.0012
4.3% (37/869) 0.0013
10.9% (94/864) 0.0001
5.4% (47/869) 0.0085
19.1% (166/869) 0.0001
75.5% (656/869) 0.0001
-to-treat population are shown.
n; LAD  left anterior descending artery; LMCA  left main coronaryXUS E
(n  9
% (71
 11
% (52
% (34
% (12
% (31
% (10
% (63
% (24
% (76
% (66
% (54
 5.6
 0.4
ntentionQCA
ermi
ess
)
85)
85)
85)
)
2)
82)
82)
2)
984)
984)
984)
979)
83)
(983)
2)
83)
3)
1)
3)
83)
83)
ntention
ociatioraphy; RCA right coronary artery; RVD reference vessel diameter;
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The TAXUS ATLAS Trial April 24, 2007:1676–83esults
aseline demographics and lesion characteristics. Both
roups were well-matched for baseline patient and visually
stimated lesion characteristics (Table 1). However, QCA
emonstrated that lesions treated with TAXUS Liberté
ere significantly more complex versus those treated with
AXUS Express (Table 2).
rocedural information and antiplatelet usage. Techni-
al success was similar between groups. The average proce-
ure time was significantly lower for TAXUS Liberté
Table 3); this benefit was maintained even when groups
ere adjusted for geographical differences or intravascular
ltrasound usage. Furthermore, the “bailout” rate was re-
uced by nearly 50% for TAXUS Liberté (p  0.0038).
Aspirin was prescribed at discharge to more than 99.5%
f patients in both groups (Fig. 3). By 12 months, 96.1% of
AXUS Express patients and 95.5% of TAXUS Liberté
atients were taking aspirin. At discharge, thienopyridines
ere administered to 99.9% of patients in each group;
owever, compliance decreased over time such that only
3% of TAXUS Liberté patients were taking a thienopyri-
ine at 6 months. At 9 and 12 months, more TAXUS
iberté than TAXUS Express patients were taking thien-
pyridines (9 months: 62.6% vs. 54.2%, p  0.0004; 12
onths: 51.9% vs. 47.4%, p  0.0521).
rimary end point. The difference in TVR between the 2
P populations was 0.94% (Table 4). The upper 1-sided
5% confidence bound of 2.98% was less than the pre-
pecified non-inferiority margin of 3.0% (p  0.0487). A
imilar outcome was demonstrated for the ITT populations.
herefore, the primary end point was met.
dditional clinical outcomes. There were no differences
etween the groups in any clinical outcomes analyzed at
ither 9 or 12 months (Table 5). Freedom from MACE or
Procedural Characteristics and Medication Usag
Table 3 Procedural Characteristics and Med
TAX
(
Technical success* 98.9
Procedure time (min) 53.0
Patients without IVUS 51.2
North American procedures 53.0
Maximum stent deployment pressure (atm) 13.4
Maximum post-dilation pressure (atm)† 15.0
Medication usage
Pre-procedure
ASA 98.5
Clopidogrel or ticlopidine 99.2
ASA and clopidogrel or ticlopidine 97.7
During procedure
GP IIb/IIIa inhibitor 52.7
Heparin/other antithrombin 97.8
Numbers shown are mean  SD (n) or % (count/sample size). Data fo
as successful delivery and deployment of a study stent to the target les
pressure for TAXUS IV control patients does not include post-dilatat
post-dilatation.
ASA  aspirin; GP  glycoprotein; IVUS  intravascular ultrasound.VR through 12 months was similar between the groups
Fig. 4).
By 12 months, there were 7 stent thromboses for TAXUS
xpress and 8 for TAXUS Liberté (p  0.63) (Table 5).
wo stent thromboses occurred in TAXUS Liberté beyond
months. An 83-year-old man suffered a stent thrombosis
ith Q-wave MI on day 258. He was taking both aspirin
nd clopidogrel at the time of thrombosis. A 45-year-old
an who had stent thrombosis and non–Q-wave MI on day
65 had discontinued clopidogrel, but was taking aspirin.
here were no sudden cardiac deaths after 30 days and out
o 12 months that could possibly be attributed to additional
tent thromboses in the TAXUS Liberté group.
Figure 3 Antiplatelet Medication Usage
in the Intention-to-Treat Population (n  1,862)
Dual therapy: aspirin plus clopidogrel or ticlopidine.
on Usage
press
91)
TAXUS Liberté
(n  871) p Value
0/991) 99.7% (867/870) 0.0637
.5 (991) 47.8  25.5 (870) 0.0052
.5 (706) 42.0  23.4 (544) 0.0004
.5 (989) 46.0  25.6 (630) 0.0010
(974) 13.8  2.7 (866) 0.0060
(431) 16.6  4.1 (414) 0.0001
6/991) 98.7% (860/871) 0.6960
3/991) 99.9% (870/871) 0.0421
6/989) 98.6% (859/871) 0.1333
2/990) 23.9% (208/871) 0.0001
8/990) 100% (871/871) 0.0001
tention-to-treat population are shown. *Technical success is defined
hout balloon rupture or embolization; †maximum post-stent dilatation
formed with the stent delivery system; not all subjects underwente
icati
US Ex
n  9
% (98
 49
 56
 49
 2.6
 3.6
% (97
% (98
% (96
% (52
% (96
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April 24, 2007:1676–83 The TAXUS ATLAS TrialCA outcomes. Baseline, post-procedure, and 9-month
ngiographies were performed on 75% of angiographic
ubstudy patients (Fig. 2B). Noninferiority was demon-
on-Inferiority Testing of Primary and Pre-Specified Secondary End
Table 4 Non-Inferiority Testing of Primary and Pre-Specified Sec
Per-Protocol Population
TAXUS Express
(n  980)
TAXUS Liberté
(n  867)
Primary end point
9-month TVR 7.01% (67/956) 7.95% (68/855)
Secondary end points
In-stent %DS 18.80 19.44 (486) 21.04 21.40 (448
In-stent binary restenosis 8.64% (42/486) 11.38% (51/448)
In-stent MLD (mm)* 2.28 0.66 (486) 2.19 0.71 (448)
In-stent late loss (mm) 0.42 0.54 (484) 0.41 0.54 (446)
Intention-to-Treat Population
Control
(n  991)
TAXUS ATLAS
(n  871)
9-month TVR 7.14% (69/967) 8.03% (69/859)
umbers shown are % (count/total) or mean  SD (n). Data for per-protocol or intention-to-treat
inimum lumen diameter (MLD).
TVR  target vessel revascularization; %DS  % diameter stenosis.
Clinical Outcomes at 9 and 12 Months in the In
Table 5 Clinical Outcomes at 9 and 12 Mon
TAXUS E
(n  9
Clinical procedural success 96.7% (31
In-hospital MACE 2.6% (26
30-day MACE 3.3% (33
4-month MACE 5.4% (53
9-month MACE 10.5% (10
Cardiac death 0.9% (9/
MI 3.9% (38
Q-wave MI 0.6% (6/
Non–Q-wave MI 3.3% (32
TVR, overall 7.1% (69
TLR, overall 4.5% (44
TVR remote, overall 2.7% (26
9-month TVF 9.8% (95
12-month MACE* 12.3% (11
Cardiac death* 1.0% (10
MI* 3.9% (37
Q-wave MI* 0.6% (6/
Non–Q-wave MI* 3.2% (31
TVR, overall* 8.9% (85
TLR, overall* 5.5% (53
TVR remote, overall* 3.8% (36
12-month TVF* 11.7% (11
9-month stent thrombosis 0.7% (7/
12-month stent thrombosis* 0.7% (7/
In-hospital 0.2% (2/
Out-of-hospital to 30 days 0.3% (3/
31–180 days 0.2% (2/
181–284 days 0.0% (0/
285–365 days* 0.0% (0/
Non-cardiac death to 12 months* 1.3% (12
Total death to 12 months* 2.3% (22
9-month outcomes are from the intention-to-treat population. Num
per-protocol population (TAXUS Express: n  980; TAXUS Liberté: n MACEmajor adverse cardiac events; MImyocardial infarction; TLR ta
vessel revascularization.trated for all pre-specified QCA parameters (Table 4).
AXUS Liberté had a significantly lower MLD pre-
rocedure; however, paired assessment of angiographic out-
s
ry End Points
Difference
(Upper 1-Sided 95% CI)
Pre-Specified
Non-Inferiority Margin
p Value for
Non-Inferiority Testing
0.94% (2.98%) 3.0% 0.0487
2.24 (4.44) 6.6% 0.0006
2.74% (5.98%) 6.3% 0.0354
0.09 (0.16) 0.17 0.0316
0.01 (0.04) 0.18 0.0001
Difference
(Upper 1-Sided 95% CI)
Pre-Specified
Non-Inferiority Margin
p Value for
Non-Inferiority Testing
0.90% (2.94%) 3.0% 0.0454
ions are shown as indicated. *Lower 1-sided 95% confidence interval (CI) is reported for in-stent
on-to-Treat Population*
n the Intention-to-Treat Population*
TAXUS Liberté
(n  871) p Value
) 96.9% (844/871) 0.8538
2.4% (21/871) 0.8825
2.8% (24/870) 0.5022
3.9% (34/869) 0.1527
) 11.0% (95/862) 0.7064
0.8% (7/862) 1.0000
3.7% (32/862) 0.9030
0.7% (6/862) 1.0000
3.0% (26/862) 0.7901
8.0% (69/862) 0.4787
5.7% (49/862) 0.2865
3.2% (28/862) 0.4911
10.8% (93/862) 0.4885
) 12.5% (106/851) 0.9354
0.8% (7/851) 0.6248
4.0% (34/851) 0.8879
0.7% (6/851) 0.8383
3.3% (28/851) 0.9515
9.2% (78/851) 0.8334
6.1% (52/851) 0.6035
4.2% (36/851) 0.6111
) 12.1% (103/851) 0.8120
0.8% (7/858) 1.0000
0.9% (8/846) 0.6318
0.0% (0/871) 0.5018
0.2% (2/869) 1.0000
0.5% (4/867) 0.4275
0.1% (1/857) 0.4709
0.1% (1/847) 0.4727*
0.5% (4/847) 0.0752
1.3% (11/854) 0.1110
own are % (count/total). *12-month outcomes are based on thePoint
onda
)
populattenti
ths i
xpress
91)
8/329
/991)
/987)
/985)
2/974
974)
/974)
974)
/974)
/974)
/974)
/974)
/971)
8/957
/957)
/957)
957)
/957)
/957)
/957)
/957)
2/954
966)
947)
991)
987)
985)
963)
945)
/951)
/961)
bers sh
867).rget lesion revascularization; TVF target vessel failure; TVR target
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The TAXUS ATLAS Trial April 24, 2007:1676–83omes showed comparable in-stent acute gain (p  0.68)
nd late loss in both groups (p  0.69) (Fig. 5). Despite the
igher lesion complexity in the TAXUS Liberté group, no
ignificant differences between the groups were found in any
f the QCA parameters analyzed at 9 months (Table 6).
iscussion
he TAXUS ATLAS trial evaluates the TAXUS Liberté
tent versus a historical control of TAXUS IV and V
atients. Despite using similar inclusion and exclusion
riteria, the contemporary TAXUS Liberté cohort had
ore complex lesions when compared with the historic
AXUS Express controls, suggesting a change in the use
f DES. Despite this increase in lesion complexity, the
linical outcomes at 9 and 12 months demonstrate that
AXUS Liberté is as safe and effective as TAXUS
xpress. Additionally, the shorter procedure time and
ower bailout rate may represent a clinical surrogate for
he improved deliverability and conformability of
AXUS Liberté. These results demonstrate the success-
ul transfer of the TAXUS technology to a new stent
latform with optimized design.
The current study compares 2 cohorts enrolled 5 to 35
Figure 4 Cumulative Freedom-From-Event Rates
(A) Major adverse cardiac events (MACE) or (B) target vessel
revascularization (TVR). Data shown are for the per-protocol population (n  1,845).onths apart. Cross comparison of baseline and proce-ural characteristics and outcomes provides insight into
he continuing change in clinical practice since the
ntroduction of DES. Even with similar inclusion and
xclusion criteria, more challenging lesions are treated
ow, suggesting an increased confidence in the benefits
rovided by DES. The duration of thienopyridine ad-
inistration has increased, which may reflect the in-
reased sensitivity to potential late thrombotic events
fter DES implantation. Finally, a more pronounced
oculostenotic reflex” (5), as suggested by the steeper
ecline in freedom-from-TVR during the mandated
ngiographic follow-up window, was observed. De-
reased visual tolerance of the operator to intermediate
e-narrowing within the stent segment since the intro-
uction of DES may contribute to this development.
The TAXUS ATLAS trial was designed as a prospec-
ive, non-inferiority trial with a historic control group to
everage the large amount of data available for TAXUS
xpress. The purpose of this trial design is to provide
roof-of-concept in a patient population controlled by
trict inclusion and exclusion criteria. As with the actively
ontrolled TAXUS trials, the historically controlled
AXUS ATLAS trial has complete data monitoring: a
Figure 5 Angiographic Measures
(A) In-stent or in-lesion minimum lumen diameter (MLD) measures over time. Data
from the intention-to-treat population (n  1,862) at pre- and post-procedure, and
from the angiographic subset (n  1,247) at 9 months. (B) Cumulative fre-
quency distribution curves for in-stent late loss as determined by quantitative
coronary angiography in the angiographic subset (n  1,247).
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April 24, 2007:1676–83 The TAXUS ATLAS Triallinical Events Committee to adjudicate clinical events,
nd an independent core lab to perform QCA analysis.
evertheless, a limitation of a historically controlled trial
s the potential for bias due to changes in practice
atterns or lack of blinding.
The TAXUS ATLAS trial shows the successful trans-
er of a proven drug/polymer combination from the
AXUS Express stent to the next-generation TAXUS
iberté stent with an optimized platform design. Despite
ncreased lesion complexity in patients treated with
AXUS Liberté, procedural characteristics suggest im-
roved deliverability and conformability of the new
AXUS stent while the clinical and angiographic out-
omes demonstrate non-inferiority of TAXUS Liberté
ersus TAXUS Express.
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9-Month Angiographic Outcomes*
Table 6 9-Month Angiographic Outcomes*
TAXU
(n
Pre-procedure
RVD 2.80
MLD, in-lesion 0.92
%DS 66.94
Post-procedure
RVD (mm) 2.85
MLD, in-stent (mm) 2.70
MLD, analysis segment (mm) 2.28
%DS, in-stent 4.43
%DS, analysis segment 19.77
9-month
RVD (mm) 2.80
MLD, in-stent (mm) 2.28
MLD, analysis segment (mm) 2.01
%DS, in-stent 18.80
%DS, analysis segment 28.47
Binary restenosis, in-stent (%) 8
Binary restenosis, analysis segment (%) 12
Acute gain
In-stent 1.77
Analysis segment 1.36
Late loss, mm
In-stent 0.42
Analysis segment 0.27
Loss index
In-stent 0.24
Analysis segment 0.30
Numbers shown are mean SD (n) or % (n). The analysis segment con
to the stent. *Data shown is for paired analysis subset, including p
coronary angiography data were available.
MLD  minimum lumen diameter; RVD  reference vessel diametssistance in drafting this manuscript.eprint requests and correspondence: Dr. Mark A. Turco,
enter for Cardiac & Vascular Research, Washington Adventist
ospital, 7600 Carroll Avenue, Takoma Park, Maryland 20912.
-mail: MTurco@ahm.com.
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4)
TAXUS Liberté
(n  543) p Value
(486) 2.77 0.50 (449) 0.3639
(486) 0.83 0.36 (449) 0.0001
3 (486) 69.92 11.88 (449) 0.0001
(484) 2.82 0.52 (447) 0.3714
(484) 2.60 0.46 (446) 0.0006
(484) 2.22 0.51 (447) 0.0615
9 (484) 7.30 8.87 (446) 0.0001
(484) 21.30 9.47 (447) 0.0169
(486) 2.75 0.49 (449) 0.1287
(486) 2.19 0.71 (448) 0.0541
(486) 1.97 0.67 (449) 0.3132
4 (486) 21.04 21.40 (448) 0.0934
4 (486) 29.15 19.06 (449) 0.5688
6) 11.4 (448) 0.1893
6) 14.3 (449) 0.3836
(695) 1.76 0.47 (539) 0.5696
(696) 1.37 0.50 (541) 0.7795
(484) 0.41 0.54 (446) 0.6872
(484) 0.25 0.50 (447) 0.5889
(484) 0.25 0.37 (446) 0.7089
(484) 0.20 0.57 (447) 0.4045
the stented segment and the 5 mm immediately proximal and distal
for whom pre-procedure, post-procedure, and 9-month quantitative
 % diameter stenosis.S Exp
 70
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0.47
0.50
0.54
0.46
0.33
2.25
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